<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

2022 Startup Stage

Hosted by:

Eli Lilly Logo

Designed exclusively for pre-series A biotech, medtech or healthtech companies.



Investing in the Future of the European Life Sciences: Maintaining Global Leadership and Expanding Abroad

At the forefront of breakthrough treatments of disease, life science business rely tremendously on funding and capital. The discovery and development of new drugs, vaccines and cell/gene therapies have placed life sciences at the frontier of responses to global challenges and new investments. These include the increasing access to digital health, ageing populations and the provision of sustainable healthcare.

  • With the advent of newer fund managers with strong life science pedigrees to both the UK, and Global Investor Ecosystems, what are the impacts on investments both home and abroad?
  • How can funds work to support the next generation of biotechs and founders?
  • How can new fund managers work collectively to ensure the longevity of investment in life sciences worldwide

Moderator: Laura Lane, VP - Venture Sciences (Europe), Eli Lilly and Company
Anne Horgan
, Partner, CIC
Marion Bernard
, Chief Investment Officer, Northern Gritstone
Owen Smith
, Partner, 4BIO Capital

Laura Lane, VP Venture Sciences - Europe, LillyAnne Horgan, Partner, Cambridge Innovation CapitalMarion Bernard, Chief Investment Officer, Northern GritstoneOwen Smith, Partner, 4BIO Capital

11:05 NanoVation Logo


11:15 Antikor Logo


11:25 Gendius Logo


11:35 Lifespin GmbH Logo


11:45 Monument Therapeutics Logo


11:55 Curileum Discovery Logo


12:05 Enbiosis Biotechnology Logo


12:15 Medherant Logo


12:25 4Tissue Logo


12:35 Ilonov Logo


12:45 LAM-X Logo


12:55 ExtraHorizon Logo


13:05 Zylorion Health Logo


13:15 HookeBio Logo


13:25 FerryX Logo


13:35 Antion Biosciences Logo



The Promise of Late-Stage Neuroscience Assets and What This Could Mean for the Financing Landscape of Early-Stage CNS Companies

Recognition that ageing populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Dementia is the most common degenerative neurological condition in the United States, with most cases coming from Alzheimer’s disease. In 2021, 653 clinical development programs for medicines to treat neurological diseases, 43% of which are for neurodegenerative medicines. On top of this, recent advances in genomics and immunology and new diagnostics and surgeries, are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.

  • Where are the current areas of highest unmet need in neuroscience? Has the pandemic affected how neuroscience assets are viewed?
  • How have recent advancements, developments and work towards long-elusive approvals in NGD reframed the landscape?
  • Which new innovations in biotechnology are fuelling novel drug discovery and development in neuroscience and how is this affecting allocation of capital?
  • How are funds being restructured and what new funds are helping to accelerate this new wave of advancements?
  • Which new innovations are fuelling novel drug discovery and development and how is this affecting allocation of capital into the space?

Moderator: Jenny Laird, VP, Search & Evaluation, Eli Lilly and Company Limited
Olivia Cavlan, Chief Corporate Development & Strategy Officer, Alchemab
Felice Verduyn-Van-Weegen, Partner, EQT Group
Hugh Nuthall, Senior Director, Search & Evaluation Neuroscience, Eli Lilly and Company
David Reynolds
, CEO, LoQus 23

Jenny Laird, VP Search & Evaluation, LillyOlivia Cavlan, Chief Corporate Development & Strategy Officer, AlchemabFelice Verduyn-Van-Weegen, Partner, EQT GroupHugh Nuthall, Senior Director, Search & Evaluation Neuroscience, Eli Lilly and CompanyDavid Reynolds, CEO, LoQus 23

14:25 Hybridize Therapeutics Logo



         Amplio Pharma

14:45 InStar Technologies Logo


14:55 Repair Biotechnologies Logo


15:05 Imophoron Logo


15:15 Sedivention Logo


15:25 Tediro Logo


15:35 ICHORtec Logo


15:45 Temisis Logo



Tetraneuron Logo


16:05 Nevragenics Logo


16:15 Captain T Cell Logo


16:25 Astrivax Logo


16:35 CyGenica Logo


16:45 PainDrainer Logo


16:55 Medical Magnesium Logo


17:05 Valo Therapeutics Logo


17:15 Close of Investival Showcase


Lifestars Logo

Awards & Gala Dinner
- Separate ticket required
- Find out more